TCM
SBIO icon

Triumph Capital Management’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Triumph Capital Management’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$646 Buy
+10
New +$548 ﹤0.01% 1705

Other funds holding SBIO

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Triumph Capital Management's SBIO Position: Q2 2026 in Review

Triumph Capital Management opened a new position in ALPS Medical Breakthroughs ETF (SBIO) in Q2 2026: 10 shares worth $646. The stake represents ﹤0.01% of the portfolio and ranks #1705 among its holdings.

9 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

  • Triumph Capital Management held 10 shares of ALPS Medical Breakthroughs ETF worth $646 as of Q2 2026.
  • ALPS Medical Breakthroughs ETF was a new Triumph Capital Management position in Q2 2026.
  • ALPS Medical Breakthroughs ETF made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1705 holding.
  • 9 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.